• LAST PRICE
    2.9600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    2.3400/ 38
  • Ask / Lots
    4.5000/ 1
  • Open / Previous Close
    0.0000 / 2.9600
  • Day Range
    ---
  • 52 Week Range
    Low 2.3000
    High 46.4000
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 3.07
TimeVolumeCALA
09:32 ET12953.09
10:03 ET31003.06
10:37 ET3003.05
10:53 ET1003.04
11:06 ET7003.04
11:36 ET1002.99
11:44 ET7003.02
01:15 ET1003
02:40 ET1002.985
02:56 ET1003.01
03:14 ET4003.01
03:16 ET2743.02
03:32 ET43003.01
03:34 ET1003.0693
03:56 ET9842.96
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCALA
Calithera Biosciences Inc
14.3M
-0.1x
---
United StatesCPHI
China Pharma Holdings Inc
6.6M
-1.8x
---
United StatesPLXP
PLx Pharma Inc
14.4M
-0.4x
---
United StatesEVFM
Evofem Biosciences Inc
15.1M
0.0x
---
United StatesKALA
Kala Pharmaceuticals Inc
16.7M
-0.1x
---
United StatesPOTN
PotNetwork Holdings Inc
182.0K
0.0x
---
As of 2022-09-30

Company Information

Calithera Biosciences, Inc. is a clinical-stage, precision oncology biopharmaceutical company. The Company is engaged in developing targeted therapies to redefine treatment for biomarker-specific patient populations. The Company is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers. The Company is opportunistically developing therapeutics outside of oncology to treat diseases with unmet needs, as is the case in cystic fibrosis. The Company's Mivavotinib is a spleen tyrosine kinase (SYK) inhibitor, which targets the constitutively activated B-cell receptor (BCR) pathway in DLBCL and other non-Hodgkin lymphomas NHLs). Its Sapanisertib is a dual target of rapamycin kinase C I/II (TORC1/2) inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells.

Contact Information

Headquarters
343 Oyster Point Blvd #200SOUTH SAN FRANCISCO, CA, United States 94080
Phone
650-870-1000
Fax
302-655-5049

Executives

President, Chief Executive Officer, Co-Founder, Director
Susan Molineaux
Chief Financial Officer, Secretary
Stephanie Wong
Senior Vice President - Development
Christopher Molineaux
Senior Vice President - Research
Francesco Parlati
Senior Vice President - Drug Discovery
Eric Sjogren

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$14.3M
Revenue (TTM)
$6.8M
Shares Outstanding
4.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.78
EPS
$-22.77
Book Value
$12.73
P/E Ratio
-0.1x
Price/Sales (TTM)
2.1
Price/Cash Flow (TTM)
---
Operating Margin
-1,563.87%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.